Plants produce a wide diversity of compounds. Broadly, these are separated into primary metabolites, which are necessary for ...

In recent years, Novogene Europe has systematically integrated state-of-the-art technologies across its service portfolio, ...

Illumina’s first quarter results reflected ongoing challenges in the global genomics market, as the company’s performance ...

The firm hopes that ETX-636's dual mechanism inhibiting mutant PI3Kα will give it an edge over competing products on the market.

A panelist discusses the evolving role of prophylactic tocilizumab in reducing cytokine release syndrome during bispecific antibody therapy, enabling outpatient treatment and improving patient ...

Illumina said adding SomaLogic would support the company’s multiomics strategy and strengthen the value of its NovaSeq X ...

Illumina is diving deeper into proteomics research with a $425 million plan to acquire SomaLogic, including its protein ...

Up To $425 Million In Total Proceeds Inclusive of Near-term Milestone Payments; $350 Million In Upfront Cash Retains ...

INCY jumps 5.1% on a global QIAGEN deal to develop a companion diagnostic for its mutCALR-targeting cancer therapy.